Anti-interferon-β neutralising activity is not entirely mediated by antibodies

Journal of Neuroimmunology

Volumn 192, Issue 1-2, 2007, Pages 198-205

  Gilli, Francesca ^a   Marnetto, Fabiana ^a   Caldano, Marzia ^a   Valentino, Paola ^a   Granieri, Letizia ^a   Di Sapio, Alessia ^a   Capobianco, Marco ^a   Sala, Arianna ^a   Malucchi, Simona ^a   Kappos, Ludwig ^b   Lindberg, Raija L P ^b   Bertolotto, Antonio ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Anti IFN antibodies; BAbs; NAbs; Neutralising activity

Indexed keywords

ALPHA INTERFERON RECEPTOR; ANTIBODY; BETA INTERFERON; BETA INTERFERON ANTIBODY; BETA INTERFERON RECEPTOR; BETA1A INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M; INTERFERON BETA SERINE; SEPHAROSE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTIBODIES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GTP-BINDING PROTEINS; HUMANS; IMMUNOPRECIPITATION; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; RECEPTORS, INTERFERON; RETROSPECTIVE STUDIES;

EID: 36749043125     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.09.025     Document Type: Article

References (38)

1. Antonelli G., Simeoni E., Bagnato F., Pozzilli C., Turrizziani O., Tesoro R., Di Marco P., Gasperini C., Fieschi C., and Dianzani F. Further study on the specificity and incidence of neutralising antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J. Neurol. Sci. 15:168 2 (1999) 131-136
2. Bertolotto A., Malucchi S., Milano E., Castello A., Capobianco M., and Mutani R. Interferonβ neutralising antibodies in multiple sclerosis: neutralising activity and cross-reactivity with three different preparations. Immunopharmacology 48 (2000) 95-100
3. Bertolotto A., Gilli F., Sala A., Audano L., Castello A., Magliola U., Melis F., and Giordana M.T. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J. Immunol. Methods 256 1-2 (2001) 141-152
4. Bertolotto A., Gilli F., Sala A., Capobianco M., Malucchi S., Milano E., Melis F., Marnetto F., Lindberg R.L., Bottero R., Di Sapio A., and Bertolotto A. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 60 (2003) 634-639
5. Bertolotto A., Sala A., Malucchi S., Marnetto F., Caldano M., Di Sapio A., Capobianco M., and Gilli F. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1294-1299
6. Brickelmaier M., Hochman P.S., Baciu R., Chao B., Cuervo J.H., and Whitty A. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-β. J. Immunol. Methods 227 (1999) 121-135
7. Chadha K., Weinstock-Guttman B., Zivadinov R., Bhasi K., Muhitch J., Feichter J., Tamano-Blanco M., Abdelrahman N., Ambrus Sr. J., Munschauer F., and Ramanathan M. Interferon inhibitory activity in patients with multiple sclerosis. Arch. Neurol. 63 (2006) 1579-1584
8. Deisenhammer F., Reindl M., Harvey J., Gasse T., Dilitz E., and Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52 (1999) 1239-1243
9. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352 (1998) 1491-1497
10. Gilli F., Bertolotto A., Sala A., Hoffmann F., Capobianco M., Malucchi S., Glass T., Kappos L., Lindberg R.L., and Leppert D. Neutralising antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 127 Pt 2 (2004) 259-268
11. Gilli F., Marnetto F., Stefanuto G., Rinaldi V., Farinazzo F., Malucchi S., Capobianco M., Caldano M., Sala A., and Bertolotto A. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Mol. Diagn. 8 (2004) 185-194
12. Gilli F., Marnetto F., Caldano M., Sala A., Malucchi S., di Sapio A., Capobianco M., and Bertolotto A. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J. Neuroimmunol. 158 (2005) 195-203
13. Gilli F., Hoffmann F., Sala A., Marnetto F., Caldano M., Valentino P., Kappos L., Bertolotto A., and Lindberg R.L. Qualitative and quantitative analysis of antibody response to IFNβ in patients with multiple sclerosis. Mult. Scler. 12 6 (2006) 738-746
14. Gilli F., Marnetto F., Caldano M., Sala A., Malucchi S., Capobianco M., and Bertolotto A. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult. Scler. 12 (2006) 47-57
15. Grossberg S.E., Kawade Y., Kohase M., Kohase M., Yokohama H., and Finter N. The neutralization of interferons by antibody. II. Neutralising antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res. 21 (2001) 743-755
16. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore R.L., Pullicino P.M., Scherokman B.J., and Whitham R.H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39 (1996) 285-294
17. Kappos L., Clanet M., Sandberg-Wollheim M., Radue E.W., Hartung H.P., Hohlfeld R., Xu J., Bennet D., Sandrock A., Goelz S., and and the European Interferon beta-1a IM Dose-Comparison Study Investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65 (2005) 40-47
18. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol. 119 (1986) 558-573
19. Kawade Y., Finter N., and Grossberg S.E. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J. Immunol. Methods 278 (2003) 127-144
20. Kiessling L.L., and Gordon E.J. Transforming the cell surface through proteolysis. Chem. Biol. 5 3 (1998) R49-R62 Review
21. Lampasona V., Rio J., Franciotta D., Furlan R., Avolio C., Fazio R., Vincet A., Comi G., Trojano M., Montalban X., and Martino G. Serial immunoprecipitation assays for interferon-(IFN)-beta antibodies in multiple sclerosis patients. Eur. Cytokine Netw. 14 3 (2003) 154-157
22. Li D.K., and Paty D.W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann. Neurol. 46 (1999) 197-206
23. Malucchi S., Sala A., Gilli F., Bottero R., Di Sapio A., Capobianco M., and Bertolotto A. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 62 11 (2004) 2031-2037
24. Miller D.H., Molyneux P.D., Barker G.J., MacManus D.G., Moseley I.F., and Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann. Neurol. 46 (1999) 850-859
25. Pachner A.R. An improved for screening for neutralizing anti-IFN-β antibodies in MS patients. Neurology 61 (2003) 1444-1446
26. Pachner A.R., Narayan K., Price N., Hurd M., and Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol. Diagn. 7 1 (2003) 17-25
27. Pachner A.R., Dail D., Pak E., and Narayan K. The importance of measuring IFNβ bioactivity: monitoring in MS patients and the effect of anti-IFNβ antibodies. J. Neuroimmunol. 166 1-2 (2005) 180-188
28. Paty D.W., Li D.K., and UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 662-667
29. Perini P., Calabrese M., Biasi G., and Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J. Neurol. 251 3 (2004) 305-309
30. Polman C., Kappos L., White R., Dahlke F., Beckmann K., Pozzilli C., Thompson A., Petkau J., Miller D., and and the European Study Group in Interferon Beta-1b in Secondary Progressive MS. Neutralising antibodies during treatment of secondary progressive multiple sclerosis with interferonβ-1b. Neurology 60 (2003) 37-43
31. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
32. Pungor E., Files J.G., Gabe J.D., Do L.T., Foley W.P., Gray J.L., Nelson J.W., Nestaas E., Taylor J.L., and Grossberg S.E. A novel bioassay for the determination of neutralising antibodies to IFN-β1b. J. Interferon Cytokine Res. 18 (1998) 1025-1030
33. Rudick R.A., Goodkin D.E., Jacobs L.D., Cookfair D.L., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Granger C.V., Simon J.H., Alam J.J., Simonian N.A., Campion M.K., Bartoszak D.M., Bourdette D.N., Braiman J., Brownschedle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauser F.E., Priore R.L., and Whitham R.H. Impact of interferon beta-1a on neurological disability in relapsing multiple sclerosis. Neurology 49 (1997) 358-363
34. Simon J.H., Jacobs L.D., Campion M., Wende K., Simonian N., Cookfaur D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Alam J.J., Fischer J.S., Goodkin D.E., Granger C.V., Lajaunie M., Martens-Davidson A.L., Meyer M., Sheeder J., Choi K., Scherzinger A.L., Bartoszak D.K., Bourdette D.N., Braiman D.N., Brownscheidle C.M., Whitham R.H., et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann. Neurol. 43 (1998) 79-87
35. Sorensen P.S., Koch-Henriksen N., Ross C., Clemmesen K.M., Bendtzen K., and Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralising antibodies during interferon-beta therapy. Neurology 65 (2005) 33-39
36. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285
37. Vallittu A.M., Halminen M., Peltoniemi J., Ilonen J., Julkunen I., Salmi A., Eralinna J.P., and and the Finnish Beta-Interferon Study Group. Neutralizing antibodies reduce MxA protein induction in interferon beta-1a-treated MS patients. Neurology 58 (2002) 1786-1790
38. WHO Expert Committee on Biological standardization. Thirty-Fifth Report. WHO Technical Report Series vol. 725 (1985), World Health Organization, Geneva